Efficacy of the mobilization of peripheral blood stem cells by granulocyte colony-stimulating factor in pediatric donors.
The advantages/disadvantages of the use of peripheral blood stem cells (PBSCs) for allogeneic transplantation still need to be clarified, particularly in children. We compared the kinetics, efficacy, and safety of PBSC mobilization by granulocyte colony-stimulating factor (G-CSF) and collection by apheresis between healthy pediatric and adult donors. A total of 19 pediatric (median age, 6 years) and 25 adult healthy donors (median age, 37 years) were given 10 micro/kg/day of G-CSF for 5 consecutive days for PBSC mobilization, which were harvested by apheresis on days 5 and/or 6. All of the donors tolerated the whole procedures. Serum trough levels of G-CSF determined by ELISA were significantly lower in the 16 pediatric donors evaluated than in adults (n = 16) on days 3 and 4 (P < 0.05). Although the WBC counts on days 4 and 5 were significantly higher in adults than in children (P = 0.006 and 0.004, respectively), the numbers of circulating CD34+ cells/unit of blood were identical. The number of blood CD34+ cells collected per unit of blood processed was identical in both donor populations. We propose that PBSCs could be effectively mobilized and collected in small children so that they could be donors for adult patients.
Kawano
Y
Y
Department of Pediatrics, University of Tokushima, Japan. ykawano@clin.med.tokushima-u.ac.jp
Takaue
Y
Y
Watanabe
T
T
Abe
T
T
Okamoto
Y
Y
Iwai
A
A
Iwai
T
T
Watanabe
A
A
Ito
E
E
Makimoto
A
A
Nakagawa
R
R
Watanabe
H
H
Sato
J
J
Suenaga
K
K
Suzuya
H
H
Ohnishi
T
T
Kanamaru
S
S
Kaneko
M
M
Kuroda
Y
Y
D000293:Adolescent; D000328:Adult; D000367:Age Factors; D001772:Blood Cell Count; D001781:Blood Component Removal; D002648:Child; D002675:Child, Preschool; D005221:Fatigue / Q000139:chemically induced; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000009:adverse effects / Q000494:pharmacology*; D019650:Hematopoietic Stem Cell Mobilization / Q000009:adverse effects; D006412:Hematopoietic Stem Cells / Q000187:drug effects; D006801:Humans; D007700:Kinetics; D000078224:Lenograstim; D008297:Male; D008875:Middle Aged; D010146:Pain / Q000139:chemically induced; D011994:Recombinant Proteins / Q000009:adverse effects / Q000494:pharmacology; D012449:Safety; D014019:Tissue Donors
D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; D000078224:Lenograstim